PRGN 5001
Alternative Names: PRGN-5001Latest Information Update: 09 Aug 2024
At a glance
- Originator Precigen Inc
- Class Antineoplastics; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Solid tumours